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tate (NMDA) antagonist phencyclidine (PCP) produces
behavioral abnormalities in rodents which are considered
a reliable pharmacological model of neurocognitive deﬁcits
in schizophrenia. Alterations in prefrontal neuronal ﬁring
after acute PCP administration have been observed, how-
ever enduring changes in prefrontal activity after sub-
chronic PCP treatment have not been studied. To address
this we have recorded cortical oscillations and unit
responses in putative cortical pyramidal cells in subchronic
PCP-treated rats (2 mg/kg twice daily for 7 days) under ure-
thane anesthesia. We found that this regimen reduced theta
oscillations in the medial prefrontal cortex. It further pro-
duced abnormal cortical synchronization in putative cortical
pyramidal cells. These alterations in prefrontal cortex func-
tioning may contribute to cognitive deﬁcits seen in sub-
chronic NMDA antagonist pre-treated animals in prefrontal-
dependent tasks.  2015 Published by Elsevier Ltd. on
behalf of IBRO.
Key words: schizophrenia, phencyclidine, PCP, neurophysi-
ology, medial prefrontal cortex, theta oscillations.
INTRODUCTION
Subchronic treatment with the non-competitive N-methyl-
D-aspartate (NMDA) receptor antagonist phencyclidine
(PCP) in rodents is used to model cognitive deﬁcits in
schizophrenia. PCP-treated rats exhibit impaired
performance on a number of behavioral tests thought to
parallel cognitive and negative symptoms of human
schizophrenia (Javitt et al., 2012; Neill et al., 2014). Deﬁ-
cits include changes in prepulse inhibition, attention,
working memory and set shifting (Egerton et al., 2008;
Neill et al., 2010). The mechanisms through which PCPhttp://dx.doi.org/10.1016/j.neuroscience.2014.12.014
0306-4522/ 2015 Published by Elsevier Ltd. on behalf of IBRO.
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157produces behavioral impairments is largely unknown,
however neurophysiological and immunohistochemical
results point to the involvement of prefrontal cortical cir-
cuits (Li et al., 2010; Kargieman et al., 2012; Celada
et al., 2013). NMDA antagonist models of schizophrenia
predict deﬁcits correlated with NMDA receptor distribu-
tion. Thus NMDA receptors are present at high density
in frontoparietal and temporal brain regions suggesting
that disruptions in this system underlie cognitive deﬁcits
associated with this condition (Javitt et al., 2012).
Impaired prefrontal cortex (PFC) function in acute NMDA
antagonist-treated rats parallels ﬁndings implicating PFC
in the neuropathology of schizophrenia. Prefrontal ana-
tomical, cellular and neurochemical alterations have been
reported in schizophrenic patients (Rajkowska et al.,
1998; Cullen et al., 2006; Ellison-Wright and Bullmore,
2010).
There is robust evidence that acute NMDA receptor
blockade alters prefrontal neurophysiological function
in vivo. In rats, acute systemic PCP administration
exerts a complex eﬀect on the discharge rate of
pyramidal neurons in medial prefrontal cortex (mPFC),
resulting primarily in excitation but also in inhibition in
some units, as well as altered ﬁring patterns and locking
to ongoing slow oscillations (Kargieman et al., 2007,
2012). The overall excitatory eﬀects of acutely adminis-
tered NMDA receptor antagonists on prefrontal activity
may be mediated by suppression of GABAergic activity
and likely results from network interactions which may
involve thalamic, basal ganglia and hippocampal regions.
Acute NMDA receptor blockade promotes hyperconnec-
tivity in functional brain networks (Dawson et al.,
2014a). This maps onto ﬁndings that positive symptom-
atology in human patients is associated with prefrontal
hyperactivity (Shergill et al., 2000). However a distinction
must be made between schizophrenia-like deﬁcits
induced with acute vs. subchronic NMDA-receptor block-
ade. Thus repeated subchronic PCP exposure produces
long-lasting behavioral deﬁcits, which far outlast the per-
iod of drug infusion (Neill et al., 2010). It also results in
sustained NMDA receptor hypoactivity and disruptions
in prefrontal metabolism, reduced expression of the
GABA marker parvalbumin, and compromised functional
integration between distributed neural systems assessed
with cerebral glucose utilization (Dawson et al., 2014b).
Prefrontal neurophysiological parameters have not
been characterized in vivo after subchronic NMDA
receptor blockade. To address this here we recorded
activity in putative pyramidal neurons in mPFC of
158 A. M. J. Young et al. / Neuroscience 287 (2015) 157–163drug-free rats with a history of repeated PCP dosing. This
ensured that the reported deﬁcits reﬂected enduring,
conformational changes brought about by PCP
pretreatment rather than acute drug eﬀects. We found
that subchronic PCP disrupted low-frequency
oscillations in mPFC and resulted in abnormal cortical
synchrony in this structure.
EXPERIMENTAL PROCEDURES
Subjects
Male Wistar rats, obtained from Charles River (Margate,
Kent, UK), weighing between 200 and 250 g on arrival
were housed in pairs on a 12-h reversed light–dark
cycle (lights on at 1900 h) at an average temperature of
21 C and humidity of 40–70%. Water and food (LabDiet
5LF5, PMI Nutrition Intl, Brentwood, MO, USA) were
freely available. The experiments were carried out under
institutional ethics approval and appropriate project and
personal license authority granted by the UK Home
Oﬃce under the Animals (Scientiﬁc Procedures) Act
1986.
PCP treatment
One week after arrival, rats received pre-treatment of
PCP hydrochloride (Sigma Aldrich, Gillingham, Dorset,
UK; product nr. P3029) (2.0 mg/kg; n= 7) or saline
(n= 8), in a volume of 1 mL/kg i.p. twice daily for
7 days. Following PCP and saline treatment, the
animals were given a 1-week drug-free period prior to
testing. The PCP dosing regimen was based on
previous work by us and others demonstrating robust
deﬁcits in exploratory and attentional paradigms and
neurochemical deﬁcits (McLean et al., 2008; Sood et al.,
2011).
Electrophysiological recordings and analysis
Acute electrophysiological recordings were performed
under urethane anesthesia (1.5-mg/kg i.p.). Body
temperature was monitored rectally and maintained at
37 C using a homeothermic pad (Harvard Apparatus,
Boston, MA, USA). For ﬂuid replacement, 5% glucose
was continuously administered via an infusion pump
(3 mL/h, s.c.; Instech, K. D. Scientiﬁc, Holliston, MA,
USA). Glycopyrronium bromide (40 lL/kg, i.m.;
Anpharm, Warsaw, Poland) was given to reduce
respiratory tract secretions. Animals were ﬁxed to a
stereotaxic frame and the head was adjusted so that
lambda and bregma were on the same horizontal plane.
To prevent corneal desiccation Lacri-Lube Eye Ointment
(Allergan, Wesport, Ireland) was applied to the eyes.
mPFC was targeted with a left-side craniotomy with
coordinates: +3.2 mm AP; 0.5 mm ML; 2 mm DV
(Paxinos and Watson, 2007). Recording electrodes con-
sisted of quartz glass-coated platinum/tungsten wires
pulled and ground to custom shapes in our laboratory
(shank diameter 80 lm; diameter of the metal core
23 lm; free tip length 8 lm; impedance, 1–3 MO; Tho-
mas Recording, Giessen, Germany). Wideband signals
were acquired continuously via an op-amp-basedheadstage ampliﬁer (HST/8o50-G1-GR, 1x gain, Plexon
Inc., Dallas, TX, USA), passed through a preampliﬁer
(PBX2/16wb, 1000x gain; Plexon Inc., Dallas, TX, USA)
and digitized at 40 kHz. For spike sorting the raw signal
was band-pass ﬁltered 300–3000 Hz and spikes were
sorted using the Matlab-based Wave_clus software to
yield single-unit spike trains (Quiroga et al., 2004).
Wave_clus performs unsupervised spike detection and
sorting using wavelets and super-paramagnetic cluster-
ing. All automatic detection thresholds and sorting solu-
tions were examined individually and adjusted if needed.
Field potentials were low-pass ﬁltered using a 200-Hz
cut-oﬀ Butterworth ﬁlter and downsampled oﬄine to
5000 Hz. Power spectral densities of the signals recorded
from PFC were estimated by means of Welch periodo-
grams (window length: 2 s, overlap: 90%, Hanning win-
dow, resolution 1 Hz/bin). Treatment eﬀects in the
energy values (mean power of all frequencies within the
band) for the delta (0.5–3.5 Hz), theta (4–7.5 Hz), alpha
(8–12 Hz), mu (10–12 Hz), beta (13–30 Hz) and gamma
(30–70 Hz) frequency bands were assessed using the
Mann–Whitney U test for equal medians. To investigate
drug eﬀects on spike-local ﬁeld potential (LFP) synchrony,
the LFP signal was band-pass ﬁltered using a 3-Hz mov-
ing window with a second-order Butterworth ﬁlter. A Hil-
bert transform was applied to obtain the instantaneous
phase for each frequency range (Fig. 3A, B) (Saleem
et al., 2010). Average phase angle for each spike at each
frequency window was calculated using the Matlab tool-
box CircStat (Berens, 2009). Further analyses were cal-
culated using Neuroexplorer (Nex Technologies,
Littleton, MA, USA) and custom-written Matlab routines.RESULTS
mPFC theta spectral power is reduced by PCP
pretreatment
Spectral analysis of LFP activity from mPFC of vehicle- or
PCP-treated rats showed that the predominant activity in
both groups was gathered in the lower frequency ranges
(Fig. 1A). Qualitatively, PCP-treated rats showed a
decrease in the energy of the oscillatory activity at the
lower frequency bands (Fig. 1B). Signiﬁcant statistical
diﬀerences emerged for the theta range (Mann–Whitney
U test, p= 0.0 4). For higher frequencies, the spectra
of both groups decayed monotonically and no prominent
activity was detected.PCP pretreatment results in abnormal cortical
synchrony
The reduction in theta power suggested deﬁcits in mPFC
synchrony. To further investigate this observation we
analyzed synchrony looking at both single-unit activity
and spike-LFP locking. We analyzed 29 units in PCP-
treated animals and 48 units in drug-naı¨ve controls. In
order to target putative pyramidal cells we recorded
from units with relatively low ﬁring rates. Firing rates did
not diﬀer signiﬁcantly across the two groups: 0.90 Hz for
saline (SEM= 0.48) and 1.12 for PCP (SEM= 0.51)
and are consistent with the cells being regularly spiking
B: PFC spectral power comparisons for individual frequency bands.
A: PFC spectral power in PCP and vehicle-treated animals
PCP
Vehicle
Fig. 1. Power spectral density (PSD) of mPFC oscillatory activity
shows a signiﬁcant decrease in theta power in PCP-treated animals.
(A) Power spectral density of mPFC oscillatory activity in vehicle- and
PCP-treated animals. Data are depicted as mean ± CI, gray traces
for vehicle, red for PCP-treated animals. (B) Box-plot representation
for the energy at each of the frequency bands of interest for the
vehicle (black boxes) and PCP-treated conditions (red boxes).
Statistical tests (Mann–Whitney U test) reveal a signiﬁcant decrease
(p= 0.04) in the energy of the theta band (4–7.5 Hz). (For interpre-
tation of the references to colour in this ﬁgure legend, the reader is
referred to the web version of this article.)
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these are largely consistent with previous work [e.g.
(Bruno and Simons, 2002); initial wave duration
(mean ± sd) was 0.64 ± 0.3036 ms and the second
phase (corresponding to spike after-hyperpolarization)
was 0.87 ± 0.34 ms]. To investigate spike synchrony
we computed the cross-correlogram of spikes recorded
simultaneously and calculated the area under the cross-
correlogram integrating over windows of varying length
(Fig. 2A). The area under the cross correlogram was sig-
niﬁcantly higher (95% bootstrapped conﬁdence intervals)
in PCP pre-treated animals over a range of window dura-
tions suggesting increased synchrony (Fig. 2B). To rule
out the possibility that cluster cutting may inﬂuence this
conclusion we calculated average auto-correlograms for
PCP and vehicle-pretreated groups; the autocorrelo-
grams did not diﬀer signiﬁcantly between conditions.During slow wave sleep, quiet wakefulness, and some
forms of anesthesia including urethane, brain states are
characterized by low-frequency, large-amplitude mem-
brane potential changes (Steriade et al., 1993; Petersen
et al., 2003). Here we found no diﬀerence in overall slow
oscillation activity (<3.5 Hz) as a result of PCP treatment
(Fig. 1). Still to rule out the possibility that spike cross cor-
relations may be diﬀerentially aﬀected by these so-called
UP and DOWN states in the drugs vs. vehicle group we
calculated the instantaneous oscillation phase of each
spike using a Hilbert transformation of the low-pass
(<3 Hz) ﬁltered LFP trace to ﬁnd spike occurrences dur-
ing UP and DOWN states. Integrated averages of cross-
correlations calculated from spike pairs occurring in either
UP or DOWN states produced similar drug diﬀerences.
Therefore we conclude that urethane-produced slow
oscillations are unlikely to account for enhanced spike
synchrony in PCP-treated animals.
Next we investigated mPFC abnormal synchronization
in PCP pre-treated animals using another, independent
metric based on spike-LFP locking. We calculated mean
resultant vector length of each single unit relative to
discrete LFP frequency components obtained by sliding
a 3-Hz-wide window along the frequency domain
(Fig. 3A, B). Resultant vector length reﬂects the
magnitude of the directionality eﬀect and thus represents
the degree of locking. Population averages clearly
revealed higher locking to lower frequencies in PCP pre-
treated animals (Fig. 3C). This ﬁnding cannot be
explained with group diﬀerences in urethane-induced
slow oscillations because delta spectral power was not
aﬀected by PCP pre-treatment (see Fig. 1B). These
results point to PCP-induced abnormal synchronization
in PFC. Taken together with observations of reduced
theta-band activity they may represent a compensatory
mechanism which in behaving animals could mask
dynamic, task-related changes in single-unit synchrony
and produce cognitive deﬁcits in PFC-dependent tasks
(Benchenane et al., 2010; van Wingerden et al., 2010).DISCUSSION
Subchronic PCP treatment in rodents produces a number
of behavioral abnormalities which model cognitive and
negative symptoms of schizophrenia. Here we studied
for the ﬁrst time prefrontal neurophysiological deﬁcits in
this pharmacological model. We found that subchronic
PCP produced distinct prefrontal deﬁcits including
disrupted prefrontal theta power and abnormal
synchronization in pyramidal cells. Consistent with the
role of prefrontal synchrony in attention, these deﬁcits
may drive cognitive abnormalities observed after
subchronic NMDA antagonist treatment.
Intrinsic oscillatory activity in the cortex underlies the
modulation, conditioning and redirection of incoming
information (Benchenane et al., 2010). In the current
study LFP spectral analyses revealed a decrease in
mPFC theta power, a frequency range involved in atten-
tion and working memory. Consistent with this observa-
tion, behavioral demands imposed by a spatial working
memory task modulate mPFC theta and subchronic
A: cross-correlation analysis
B: cross-correlation based synchrony
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Fig. 2. Spike cross-correlations reveal abnormal prefrontal syn-
chrony in PCP-treated animals. (A) Illustration of the cross-correla-
tion-based analysis from two mPFC units recorded simultaneously;
area under the cross-correlation was integrated over windows of
varying length and plotted in (B). Spike waveform error bands
represent SD. (B) Cross-correlogram-based synchrony was signiﬁ-
cantly higher in PCP-treated animals for a range of integration
windows. Error bars represent a 95% bootstrapped conﬁdence
interval.
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working memory (Mandillo et al., 2003). PCP eﬀects on
theta power may suggest dysregulation of local inhibitory
circuits which is consistent with immunochemical studies
in PCP-treated rats and post-mortem schizophrenic
brains (Beasley et al., 2002; McKibben et al., 2010). Work
in the hippocampus shows that theta oscillations are
modulated by GABA transmission and that ﬁring of par-
valbumin-positive GABA neurons is strongly coupled to
theta (Klausberger and Somogyi, 2008; Yu et al., 2013).
GABA transporter 1 knockout mice show reduced hippo-
campal theta and behavioral abnormalities related to
schizophrenic symptoms which may be speciﬁc toprefrontal GABA transmission (Gong et al., 2009). At
present it is not clear whether the disruption of theta activ-
ity observed here is secondary to alterations in hippocam-
pal theta. Thus Df(16)A+/ mice, a model of a recurrent
genomic disorder with strong links to schizophrenia and
cognitive dysfunction, show disrupted prefrontal-hippo-
campus LFP coherence (Sigurdsson et al., 2010). Pre-
frontal theta power was not altered in Df(16)A+/ mice
and behavioral abnormalities in this mouse line are diﬀer-
ent from the one observed in the chronic PCP model: the
authors report spontaneous hyperactivity whereas hyper-
locomotion is not seen in repeated NMDA-antagonist-
treated rodents tested drug-free (Stark et al., 2008). How-
ever while some but not all rodent models show disrupted
prefrontal hippocampal coherence, recent work suggests
that mPFC theta does not depend on hippocampal input
as inactivation of the ventral hippocampus had no eﬀect
on mPFC theta (O’Neill et al., 2013). Notably, these mod-
els are in contrast with EEG measurements in schizo-
phrenic patients which show increased power in the
lower frequency bands including theta although
decreases in delta power during sleep have also been
reported (Keshavan et al., 1998; Sekimoto et al., 2007;
Narayanan et al., 2014). The use of anesthesia in the cur-
rent study, the global nature of the EEG readout and med-
ication eﬀects in patients may contribute to these
diﬀerences; further work is clearly required to better
map these models to neuropsychiatric variables.
Here we also report abnormal synchrony in mPFC of
PCP-treated animals. Pyramidal cells showed stronger
cross-correlations and abnormally high locking to lower
frequency bands of ongoing LFP oscillations. On the
other hand acute MK-801 treatment results in reduction
of mPFC ﬁring synchrony (Molina et al., 2014). Thus our
ﬁnding appears speciﬁc to negative symptomatology with
which the subchronic PCP model is most strongly associ-
ated and is consistent with in vitro observations of hyper-
sensitive responses of mPFC neurons to NMDA and
depolarizing currents (Arvanov and Wang, 1999; Ninan
et al., 2003). Cognitive tasks in drug-naı¨ve rodents may
oﬀer clues about the functional signiﬁcance of the disrup-
tions observed in the present study. Thus orbitofrontal sin-
gle units lock to theta-band oscillations during reward
expectation and current source density analysis suggested
a local source of the theta oscillation (vanWingerden et al.,
2010). Reward expectation also enhanced theta power in
this study. Increased baseline locking as reported in the
current study may mask phasic synchrony-based signals
driving attentional deﬁcits in this model.
The mechanisms of acute vs. sub-chronic PCP
treatment are likely to be diﬀerent. Acute PCP results in
robust increases in locomotor activity whereas overall
baseline activity was not increased after repeated
NMDA receptor antagonist dosing in rats or mice
[(Mandillo et al., 2003; Schlumberger et al., 2009;
Beninger et al., 2009); but see also (Jentsch et al.,
1998)]. Acute NMDA-antagonist treatment may recapitu-
late the acute psychotic symptoms of the disorder
whereas chronic NMDA antagonist treatments may be
more closely related to cognitive deﬁcits and negative
symptoms (Dawson et al., 2014b). Patients in the
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Fig. 3. mPFC putative pyramidal neurons show enhanced synchrony with lower LFP frequencies in PCP-treated animals. (A) Example of single-
unit activity in a neuron recorded from a PCP-treated animal (top) juxtaposed to ongoing LFP oscillations (middle) recorded from the same electrode
and ﬁltered at 1–5 Hz (green trace). The instantaneous phase (bottom) of the 1–5-Hz oscillations is obtained using a Hilbert transformation. It was
used to calculate resultant vector length for spike times relative to the phases of the 1–5-Hz frequency band as shown in the polar plot on the right.
Resultant vector length reﬂects the magnitude of the directionality eﬀect and thus represents the degree of locking. (B) Example of single-unit
activity juxtaposed to ongoing LFP oscillations in a neuron recorded from a saline-treated animal; data are represented as in (A). (C) Population
locking of single units across frequencies for PCP and saline-treated animals. Neurons recorded in PCP-treated animals showed enhanced locking
to lower frequencies. Error bands are calculated across neurons and represent SEM. (For interpretation of the references to colour in this ﬁgure
legend, the reader is referred to the web version of this article.)
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show enhanced fronto-temporal BOLD connectivity dur-
ing a working memory task compared to negative cou-
pling in controls (Crossley et al., 2009). Consistent with
this, recent fMRI work shows increased connectivity
within PFC in rats after acute ketamine administration
(Gass et al., 2014). On the other hand, subchronic PCP
produces compromised functional integration including
between hippocampus and PFC (Dawson et al., 2014b).
Thus the deﬁcits we report here are likely to be due to rel-
atively permanent synaptic adaptations in PFC resulting
from repeated PCP-produced activation (Elsworth et al.,
2011). Acute systemic PCP or MK801 administration pro-
duces tonic excitation of PFC neurons and increases
dopamine eﬄux and these eﬀects may be mediated by
hippocampal input to PFC rather than local eﬀects of
the drug (Blot et al., 2013; Moghaddam and Adams,
1998; Jodo, 2013). On the other hand repeated adminis-
tration produces structural changes in mPFC synapses
suggesting that neurophysiological deﬁcits have a local
origin. Our results reinforce the hypothesis that schizo-
phrenia-like symptomatology seen in rats after sub-
chronic PCP treatment is diﬀerent from deﬁcits produced
by acute PCP. Thus in parallel with results in increased
locomotion in rodents after acute NMDA antagonist
administration, in humans deﬁcits produced by acute ket-
amine administration correlate with levels of prefrontal
dopamine release (Aalto et al., 2005). On the other hand,
the decreases in theta power observed in the current
study are likely to be unrelated to prefrontal dopaminergictransmission because mPFC iontophoretic application of
dopamine has no eﬀects on prefrontal theta power
(Benchenane et al., 2010). This is consistent with evi-
dence for non-dopaminergic mechanisms of PCP-
induced cognitive abnormalities (Carlsson and Carlsson,
1989; Koek et al., 1989). This study represents the ﬁrst
analysis of prefrontal neurophysiological sequela of sub-
chronic NMDA antagonist administration in rats. We
found that repeated PCP treatment disrupts mPFC theta
oscillations. It further produced abnormal cortical synchro-
nization in pyramidal cells. Consistent with the role of pre-
frontal synchrony in attention, these neurophysiological
deﬁcits may drive widely reported cognitive abnormalities
after subchronic NMDA antagonist treatment.
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